# A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis

> **NCT07330934** · PHASE2 · RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 403 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Placebo
- **DRUG:** IBI356

## Key facts

- **NCT ID:** NCT07330934
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-31
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 403 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07330934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07330934, "A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07330934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*